Could cutting dialysis sessions in half improve life for seniors?

NCT ID NCT07738731

Not yet recruiting Disease control Sponsor: Queen's University Source: ClinicalTrials.gov ↗

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This study tests whether elderly patients starting dialysis for kidney failure can receive treatments twice a week instead of the usual three times, without increasing hospitalizations or death. The goal is to see if fewer sessions allow patients to spend more days at home and improve their quality of life. Researchers will compare outcomes like days alive and out of hospital, overall well-being, and healthcare costs between the two treatment schedules.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Twice weekly hemodialysis compared to thrice weekly hemodialysis
What this could lead to: If fewer dialysis sessions work as well, elderly patients could spend more time at home and enjoy a better quality of life, while easing the burden on healthcare and the environment.
What could go wrong: This is a large but still early-stage study; results may not apply to all patients, and there is a risk that less frequent dialysis could lead to worse health outcomes for some.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE KIDNEY DISEASE (ESKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END-STAGE KIDNEY DISEASE (ESKD) HEMODIALYSIS

Contacts and locations

Locations

CHUM

Montreal, Quebec, Canada
Centre de Recherche du CHU de Quebec: Laval University

Québec, Quebec, Canada
Dalhousie University

Halifax, Nova Scotia, Canada
Hopital Maisoneuve-Rosemont

Montreal, Quebec, Canada
Hopital du Sacre-Coeur-de-Montreal

Montreal, Quebec, Canada
Hopital du Sacre-Coeur-de-Montreal

Montreal, Quebec, Canada
Hôpital du Haut-Richelieu

Montreal, Quebec, Canada
McGill University

Montreal, Quebec, Canada
Memorial University

St. John's, Newfoundland and Labrador, Canada
Multiple Sites

Vancouver, British Columbia, Canada
Queen's University

Kingston, Ontario, K7L 4B7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.